12
Participants
Start Date
August 31, 2010
Primary Completion Date
March 31, 2016
Study Completion Date
March 31, 2016
gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
Patients will receive gemcitabine IV and cisplatin IV on days 1 and 8. Everolimus orally will be administered continuously (one cycle = 21 days). Everolimus will be escalated at the following dose levels: 5mg every-other-day, 5mg daily, and 10mg daily. Patients will receive a total of 6 cycles of gemcitabine and cisplatin in combination with Everolimus unless disease progression or unacceptable toxicity occurs.
Memorial Sloan Kettering Cancer Center, New York
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER